Get definite about definitive drug tests to avoid the attention of auditors
Practices that report definitive drug tests continue to struggle with high denial rates, the latest Medicare Part B billing data for the tests shows. Because CMS has worked to curb improper reporting of the services, continued high denials may trigger audits and other intrusive measures. If investigators get involved, they could use strong-arm methods to wring large settlements out of practices.
To read the full article, sign in and subscribe to the DecisionHealth Newsletters.